The immune system is the natural defense of the body. It protects us every day from germs and harmful substances. However, in some serious illnesses such as cancer and autoimmune disorders, the immune system may not be able to recognize the threat, or the immune system might experience difficulties fighting it on its own. Immunotherapy drugs help boost or guide the immune system to improve its response.
This blog explains what immunotherapy drugs are and their types available in the immunotherapy drugs market. It also covers the major immunotherapy drug companies shaping the market landscape.
Immunotherapy Drugs: Overview
Immunotherapy drugs are medicines that help the body’s immune system work better. These drugs don’t make use of strong chemicals or radiation to directly kill harmful cells. Instead, they boost or guide the immune system. That way, the drugs can find and destroy those cells on their own.
Immunotherapy drugs have become highly important in the cancer immunotherapy market. Both healthy and unhealthy cells are attacked by traditional methods such as chemotherapy. This can result in various side effects. Immunotherapy, on the other hand, is more precise. The specific immune cells activated by the method can identify and attack cancer cells while keeping most healthy cells unharmed.
Types of Immunotherapy Drugs
Checkpoint Inhibitors
Checkpoint inhibitors stop immune cells from attacking healthy tissues. As powerful fighter, immune cells called T cells can cause damage to healthy tissues. There are checkpoint proteins in the body that prevent this from happening. These proteins manage the flow of signals that inform T cells when to fight or stand down. Making T cells stand down prevents them from overreacting and causing damage to healthy cells. However, these checkpoints may also lead to cancer cells escaping the T cells. Immunotherapy drugs halt checkpoint proteins from telling the T cells to stand down.
Adoptive Cell Therapy
Adoptive cell therapy involves making changes to T cells in a lab setting. The two main adoptive cell therapy types are CAR T-cell therapy and tumor-infiltrating lymphocytes (TIL). In technologies from the CAR T-cell therapy market, T cells from the body are removed, and changes are made to them. The changes result in the development of a protein called CAR that allows them to fight against cancer. The cells are then placed in the body. TIL involves removing T cells from the tumor and testing them to identify the best cancer fighters. Copies of those specific T cells are then made and placed back in the body.
Monoclonal Antibody Therapy
This therapy makes use of antibodies from the monoclonal antibodies market. These antibodies dight against cancer in several ways. Some block proteins needed by cancer cells to grow. Flagging of cancer cells to destruct them is done by others. Some monoclonal antibodies inject radioactive or toxic material in cancer cells to destroy them. Monoclonal antibody therapy is also considered as a form of targeted therapy by healthcare providers.
Immunotherapy Drugs Market Metrics
The market for immunotherapy drugs is expected to witness sustained growth in the years to come. The immunotherapy drugs market stood at USD 286.01 billion in 2024. The market is projected to account for a CAGR of 15.0% between 2025 and 2034.
Key Companies Offering Immunotherapy Drugs
Abbvie Inc.
Abbvie Inc. has a significant portfolio and pipeline in immunology. Its drugs primarily target the immune system for autoimmune diseases. Humira is the company’s major immunology product used for autoimmune diseases. Skyrizi, an anti-IL-23 antibody, is offered by the company for use in the treatment of immune-mediated diseases. Abbvie has made significant investments in the discovery and development of next-gen immuno-oncology and immunology assets.
Amgen Inc.
Amgen Inc. is a biopharmaceutical company with a major focus on the immunotherapy drugs market. The company has developed and commercialized various immunotherapy drugs. It also continues to advance its pipeline through internal research and strategic collaborations. BLINCYTO is an antibody construct by Amgen Inc., indicated for the treatment of refractory B-cell precursor acute lymphoblastic leukemia. The company offers T-cell engager, IMDELLTRA, that binds to DLL3 on tumor cells and CD3 on T cells.
AstraZeneca
The primary immunotherapy drugs by AstraZeneca are Imfinzi and Imjudo. Imfinzi is a human monoclonal antibody that targets the PD-L1 protein. It blocks the interaction of the protein with PD-1 and CD80 proteins on T-cells to improve the immune response. Imjudo is an anti-CTLA-4 human monoclonal antibody that helps activate the immune system by promoting T-cell activity. These drugs are approved for various indications, including non-small cell lung cancer, hepatocellular carcinoma, and biliary tract cancer.
Bristol-Myers Squibb Company
Bristol Myers Squibb (BMS) manufactures various immunotherapy drugs. Its immunotherapy medications include Opdivo, Yervoy, Opdualag, and Abecma. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that helps the immune system attack cancer cells. Opdualag is an immunotherapy combination that targets both the PD-1 and LAG-3 checkpoints. The company also has a robust research program that focuses on expanding the use of immunotherapy.
F. Hoffman-La Roche Ltd.
F. Hoffman-La Roche Ltd. focuses on cancer immunotherapy. Tecentriq is the foundational cancer immunotherapy for Roche. As a monoclonal antibody, Tecentriq binds with the protein PD-L1 found on tumor cells. Tecentriq has been approved for various cancers, including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, and metastatic urothelial cancer. Roche has also made significant investments in the development of new immunotherapies.
What’s Latest in Immunotherapy Drugs Market?
October 2025: Roche revealed that the U.S. FDA approved the combination of lurbinectedin (Zepzelca) and Tecentriq (atezolizumab) for maintenance therapy in adults with extensive-stage small cell lung cancer. The subcutaneous formulation of Tecentriq was also approved.
October 2025: Innovent Biologics announced a strategic global partnership with Takeda. According to Takeda, the partnership will focus on advancing next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) cancer therapies.
Conclusion
The immunotherapy drugs market is changing healthcare. These drugs are helping the immune system fight infection in a more natural way. They strengthen their own defenses of the body so they can target harmful cells in a more accurate way. As research continues, the leading immunotherapy drug companies are expected to introduce medications that provide better outcomes and have fewer side effects.
.png)
